This is what it’s all about

Truthman30 made a comment on one of my recent posts …Let’s get Paxil out of mouths and into the garbage, that’s where it belongs…

I think he’s hit the nail on the head

“The thing is , it should never have been licenced…

I have long been calling Seroxat the mental health thalidomide, even before the recent indications of Seroxat inducing malformations in new-borns I had thought of it as such. But, I wasn’t prepared for the absolute shock and horror I experienced when I read the news last year about these poor babies being harmed by this defective and toxic medication. It is an absolute and total disgrace, and GSK should be paying for Public Health Adverts on TV and full page adverts in every newspaper and magazine alerting everybody about this. It is another thalidomide and I wonder for how long will the governments and mainstream media continue to ignore the facts of this disgusting assault on human life. I suspect this ignorance is down to a fear of losing advertising revenue and for MP’s it is a fear of losing jobs in their constituencies but surely, there are people brave enough to challenge this? This madness has to stop.

GSK spend millions every week promoting their bogus drugs but they don’t seem to care when their drugs do harm. Instead they play down the horrific consequences and still even in the face of undeniable proof of harm, and stacks of evidence, they continue to deny the truth. The Seroxat Scandal and its legacy is beyond reason, and it stems from a system which has been gorging itself on “Greed” for far too long. And it is a system which has rotted itself to death. It is deeply flawed and it has failed. This has to change.

It is beyond belief enough that Seroxat was still allowed a licence after the evidence of its increased risk of suicide and aggression in children and adults. But how in the name of god can anyone argue its “benefits” now considering the damage it is causing to these babies.

I would not have believed the stuff I have read about Seroxat before I started to investigate it. But, unfortunately the Seroxat Scandal is all too real and people’s lives have been destroyed because of corruption, opportunism and a complete lack of respect for human life and dignity from all of the parties involved. The Seroxat story is not just a mental health catastrophe of epic proportions; it is an assault and an abuse of human rights. It is a chemical holocaust.

The Scandal that is Seroxat brings every societal structure into question. From the patient groups funded by pharmas , to the GPs taking perks from Pharmas to promote and endorse drugs , to the drug reps encouraged to lie about side effects. And Not only does it have huge implications for the medical and pharma community, it also highlights the failure of drug regulation because of a pharma funded system which the government is responsible for, a Government which seems intent on protecting the interests of Big Business before the health of the public.

It also begs us to question the ethos and doctrine of biological psychiatry which has spawned into a multi billion-dollar industry itself because of its all too eager collusion with the drug companies. And because of the fraud and crimes of biological psychiatry, the “mentally ill” have been further stigmatized, alienated, murdered, maimed and harmed.

“Mental illness” has become bastardised, bought, sold and squandered and the profits from this bastardisation have been soaked in misery, blood and tears from the patients who have been the innocent victims of this rancid regime.

We can forget the word “patient”; the public are merely marketing “targets” in this system dominated by an insatiable and blatant greed. We can forget the word “victim” and replace it with “statistic”, because at the end of the day, it is profits, stocks and shares, which are valued before life, health and well being. We can forget also the word “medicine”, it no longer means a “remedy” for a “malady”, “Medicine” means “product”… And the sick patient in need of healing has been replaced with ” a consumer in need of a brand of a drug”.

This may be a cynical world and I admit after being exposed to Seroxat and all that has subsequently entailed, I have become a cynic myself but I urge anyone involved in promoting Seroxat to question their conscience and to read about the Seroxat induced malformations in new-borns and I urge them also to question their integrity as human beings. I do hope that this madness fuelled by greed can be conquered by the compassion which every human being is capable of but beyond that.. I really don’t know.”

http://seroxatkillsbabies.wordpress.com/

The good works of the Diabetes Monitoring Forum

I’ve just found this news item on the internet about the Diabetes Monitoring Forum and one of its early successes. It seems that the DMF developed important new patient guidelines in the form of an advice card.

New Patient Guidelines Developed to Help Prevent Deaths From Diabetic Ketoacidosis
Diabetic ketoacidosis (DKA), a complication of diabetes resulting from insufficient insulin, can lead to coma and eventually death if it is not controlled. Minimising the likelihood of developing DKA is the first priority for the newly set up Diabetes Monitoring Forum, which has created new blood ketone monitoring advice for patients.

Today at the annual Professional Conference of Diabetes UK in Glasgow the Forum presented the evidence-base supporting the development of this new advice card.

The catalyst for the card’s creation stems from a recent advance in monitoring technology, which enables patients to measure both blood glucose and blood ketones using the same device.

The new advice card was necessitated (is this really a word?) by a recent advance, whereby people with diabetes can now monitor blood ketones, with a meter that measures both blood glucose and blood ketones, the Optium Meter from MediSense, a division of Abbott Laboratories.

The new advice card, which will be made available through the healthcare team and launched later this year, provides a simple set of instructions for people with diabetes. It helps them to adjust their treatment according to the level of blood ketones detected by their monitor. Previously, the only way for people to keep a check on diabetic ketoacidosis was by measuring urinary ketones.

Read on here for more information about the new patient guidelines developed by the DMF, which I think I should point out is not an advert for the new Optium Meter from MediSense, a division of Abbott Laboratories. No really, it isn’t…

As for the DMF “…part of the overall mission of the Diabetes Monitoring Forum, which is to optimise the role of blood glucose and blood ketone monitoring in the management of diabetes. The Forum aims to achieve this by creating and evaluating advice and practical materials for both people with diabetes and healthcare professionals.”

To find out more you were asked to contact Dr Neil Bindemann at PRiMED Communications (PRiMED changed its name to Innervate on 16 March 2004).

All in all, I think it’s apposite to finish once again with the immortal words of Jim Thomson “… ask yourself one question…What does this person, or this organisation, have to gain from taking this position? All may become marginally clearer. Jim.”

More Astroturfing?

Remember what Jim Thomson wrote recently “… ask yourself one question…What does this person, or this organisation, have to gain from taking this position? All may become marginally clearer. Jim.”

I’d like you to hold that thought while we look at some facts about the The Diabetes Monitoring Forum (DMF), an organisation set up (and run?) by Innervate – “Making Connections in Healthcare”

You remember Innervate, I’m sure, Jim Thomson used to be Business Development Director with them, although he plays down his time there, telling us “Nor do I work for Innervate. I did for a short time, while I was trying to establish the Centre for Mental Health.” More on this particular issue another time, but for the moment I’m glad Jim’s cleared things up for us.

Back to the DMF – on its website, we are told:
“The Diabetes Monitoring Forum (DMF) is a group of diabetes healthcare professionals who came together with the aim of helping people with diabetes better understand the role of blood glucose and ketone monitoring in diabetes management.”

However, on the Innervate website we are told:
“The Diabetes Monitoring Forum, is a multidisciplinary group of healthcare professionals. The group was brought together by Innervate to develop practical education material that offers simple advice on appropriate blood glucose monitoring and blood ketone monitoring for people with diabetes. The DMF, with the help of Innervate, has more recently run a number of PCT workshops providing further support on blood glucose monitoring to primary care professionals.”

Spot the subtle but important difference?

Now, The sponsor of the DMF is Abbott Laboratories.

Abbott Diabetes Care was established in April 2004 after the acquisition of TheraSense™ Inc adding to the Abbott Laboratories company portfolio, which already included MediSense®. Abbott Laboratories is one of the largest and most innovative diagnostic companies in the world, with a presence in more than 130 countries.

Abbott Diabetes Care develops, manufactures and markets blood glucose monitoring systems that enable people with diabetes to manage their condition more effectively. Abbott Diabetes Care believes that the convenience and simplicity of its products promotes increased compliance by individuals with diabetes and provides more effective management of their condition. The convenience and simplicity of the blood glucose meters is illustrated in the product information sections of abbottdiabetescare.co.uk.

I wonder if Abbott is a client of Innervate’s?

I think the only way to finish off this post is with those wise words of Jim Thomson: “… ask yourself one question…What does this person, or this organisation, have to gain from taking this position? All may become marginally clearer. Jim.”

It’s all going wrong for Jean-Pierre Garnier at Glaxo

As Chief Executives go, JP Garnier has always been VERY well paid. But in order to justify his huge salary JP needs to deliver – and he’s not – in fact, he is fast becoming an embarrassment to the company. When Garnier said “I’ll be a hero in three years.” (5 May 2004), I’m not quite sure this is what he had in mind!

At Glaxo’s AGM last week shareholders voiced their anger over the poor performance of GSK’s share price, which has dropped by almost 15% over the past year.

GSK investor John Farmer blasted the group for its “colossal under-performance” and demanded the resignation of chairman Sir Christopher Gent and a more speedy exit for CEO Jean-Pierre Garnier. Garnier is not due to step down until May 2008.

The current controversy over Avandia, the latest in a long line of scandals associated with Glaxo and its drugs, has seen more than £9 billion wiped off the share price.

New data that shows Avandia dramatically increases the risk of heart attacks, has seen frightened patients abandoning a long-term trial of the drug that is aimed at proving its safety. Glaxo has become so alarmed at the threat to the 4,400-patient safety study that it is examining ways to persuade volunteers to stick with the drug.

Perhaps Glaxo could get Sir Christopher to write to all the patients and tell them what he told the AGM “We remain confident that the significant benefits of the medicine continue to outweigh any treatment risks.”

Yep, that should do it…

Or maybe a word from JP himself would help all Glaxo’s frightened patients: “If anyone thought drugs were without side-effects, hopefully that’s over. All drugs have side-effects. We are having to spend hundreds of millions of dollars on lawyers.” Jean-Pierre Garnier 23 April 2005

Glaxo share price down further still as Avandia prescriptions reach… ZERO

It’s not looking good for Glaxo as prescriptions for Avandia reach… a bit fat ZERO.

Glaxo Avandia Prescriptions Fall, Deutsche Bank Says –
writes Andrea Gerlin at Bloomberg May 29

Avandia’s share of new oral diabetes prescriptions fell to about zero from 10 percent in the two days after the May 21 report in the New England Journal of Medicine, Deutsche Bank analysts wrote in a note. Takeda Pharmaceutical Co.’s diabetes drug Actos’ share climbed to 22 percent from 10 percent, the analysts wrote, citing data from market research firm Impact Rx.

“This reaction is far worse than we had anticipated and suggests that there could be as much as 22 percent downside risk to GSK’s near-term earnings, suggesting that there is still further downside to GSK’s share price,” the analysts wrote.

The publication of the Cleveland Clinic study caused Glaxo shares to decline 9 percent last week, cutting $13.7 billion from the company’s market value. The stock fell 24 pence, or 1.8 percent, to 1,310 pence at 2:36 p.m. in London.

The New England Journal article said users of Avandia, the London-based drugmaker’s second-best-selling medicine, were 43 percent more likely to have a heart attack and had a 64 percent increase in the risk of death than those given other drugs.

Charities and their good works – a final statement

So it seems that I am not going to be able to discuss specifics about Jim Thomson’s work at Depression Alliance with him.

We now have his final statement on all related matters which can be read over at Seroxat Sufferers, along with details of some of the conversations between Jim and Bob Fiddaman.

Jim’s statement ends:
“I wish the readers of this blog nothing but the best – and in particular I wish you all good health. Above all, I ask you all to do this one thing. When you see or hear anything in this context, ask yourself one question…”What does this person, or this organisation, have to gain from taking this position?” All may become marginally clearer. Jim”.

All I can do is to echo Jim’s words and support this particular sentiment – “…ask yourself one question… What does this person, or this organisation, have to gain from taking this position?”

Ironically, that was how all this started for me – charities-web.pdf

However, for things to become REALLY clear, I think you must also ask “and who funds this person or organisation?”

Up to 100,000 heart attacks might be linked to Glaxo drug

This from the Washington Post last Friday (thanks to Truthman30 for the link):

FDA Study Said to Show Avandia Risk
By MARILYNN MARCHIONE

The government’s own preliminary evaluation of the diabetes pill Avandia confirms the heart risks reported in a study earlier this week and suggests that as many as 60,000 to 100,000 heart attacks might be linked to its use since it came on the market eight years ago, a leading member of Congress said Thursday.

In a floor statement placed in the Senate record, Sen. Charles Grassley also said that safety watchdogs within the federal Food and Drug Administration “several months ago” recommended a “black box” on the drug’s label – the strongest possible warning.

It is the first confirmation that the FDA’s own analysis of Avandia shows a similar magnitude of heart attack risks – dangers that were first publicly raised in a medical journal report published earlier this week.

Grassley complained that FDA higher-ups have said they want to wait for results of an ongoing study that will not be available for two more years before making a decision.

“That’s a long time from now when you have millions of Americans taking this drug,” said the statement by the Iowa Republican. “Those numbers seem like a high enough threshold to me for the FDA to warn the American people of the possibility of a problem.”

The FDA has been under fire since Monday’s report came out, attacked by consumer advocates for dropping the ball on drug safety and for taking no stronger action in light of the new warning signs.

Avandia, sold by the British company GlaxoSmithKline PLC, is a blockbuster medication used to treat Type 2 diabetes, the most common form of the disease. More than 6 million people worldwide have taken the drug, whose U.S. sales topped $2.2 billion last year.

The entire article can be read here.

And in the UK, what is the MHRA doing about this, I wonder?

%d bloggers like this: